Bis-heteroaryl Derivatives Targeting Early Protein Aggregation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current inhibitors of protein aggregation, particularly for neurodegenerative diseases like Alzheimer's and Parkinson's, lack desirable pharmaceutical properties and specificity in targeting early aggregation processes, which are crucial for effectively addressing the neurotoxicity associated with protein misfolding.
Innovation Solution
Development of bis-heteroaryl derivatives, specifically compounds of Formula (III), which modulate protein aggregation by targeting specific regions of proteins like α-synuclein, thereby inhibiting their oligomerization and membrane interactions, and are formulated into pharmaceutical compositions for therapeutic use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current inhibitors of protein aggregation are used, then protein aggregation may be inhibited, but they lack desirable pharmaceutical properties and specificity in targeting early aggregation processes
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features (bis-heteroaryl derivatives with particular substitution patterns) that target specific regions of misfolded proteins (such as the NAC region of α-synuclein). This localized targeting approach enables selective inhibition of early aggregation processes while maintaining pharmaceutical properties, resolving the contradiction between specificity and manufacturability.
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters of the inhibitor compounds (such as heteroaryl ring types, substitution positions, and functional groups) to optimize both binding affinity to early aggregation intermediates and pharmaceutical properties. This allows tuning of the inhibitor characteristics to achieve both high specificity and desirable pharmaceutical profile.
2Object-affected harmful factors
If compounds target early aggregation processes specifically, then neurotoxicity may be reduced, but current compounds lack the desired pharmaceutical properties for effective therapy
Solution Approach 1:
The patent uses intermediary compounds (bis-heteroaryl derivatives) that mediate between the misfolded proteins and their aggregation pathways. These compounds act as molecular mediators that bind to early aggregation intermediates with high specificity, preventing their progression to toxic aggregates while maintaining favorable pharmaceutical properties for therapeutic use.
Solution Approach 2:
The patent applies composite material principles by creating molecules with combined heteroaryl structural motifs that integrate multiple functional elements into a single compound. This composite structure enables simultaneous achievement of high binding specificity to early aggregation intermediates and desirable pharmaceutical properties including solubility, stability, and bioavailability.
Data Source
AI summary
The present invention relates to certain bis-heteroaryl compounds, pharmaceutical compositions containing them, and methods of using them, including methods for preventing, reversing, slowing, or inhibiting protein aggregation, and methods of treating diseases that are associated with protein aggregation, including neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, Lewy body disease, Parkinson's disease with dementia, fronto-temporal dementia, Huntington's Disease, amyotrophic lateral sclerosis, and multiple system atrophy, and cancer including melanoma.